#London #United Kingdom #Turbine #Beiersdorf #Interactive Partners

Turbine Advances Drug Discovery with New Funding and Partnerships

Turbine, renowned for its cutting-edge virtual biology technology, has successfully completed a $25 million Series B financing round. The funding was led by Interactive Venture Partners, alongside contributions from Beiersdorf Venture Capital and additional investors like MSD Global Health Innovation Fund and Accel. This injection of capital is expected to propel Turbine's growth by expanding its unique virtual cell platform across various industries, particularly in the biopharmaceutical sector.

Aiming for Breakthroughs in Immunology

In conjunction with the funding, Turbine has announced a significant partnership with one of the top 10 pharmaceutical companies, marking a strategic focus on immunology. This collaboration aims to leverage Turbine's virtual assays to model immune cell behavior more effectively. By utilizing proprietary datasets from their pharmaceutical partner, Turbine intends to deliver important insights into immune pathways that can inform the development of new therapeutic combinations. This innovative partnership is set to enable pharmaceutical scientists to conduct virtual experiments on a larger scale, ensuring that only the most promising hypotheses translate into physical lab validations.

Szabolcs Nagy, CEO and Co-Founder of Turbine, explained the necessity of virtualization within the context of complex biologic diseases.

"Combination therapies have been proven to offer patient benefit; however, due to the intricate nature of immunological diseases, virtualization represents the most efficient method for exploring and identifying optimal drug combinations."

Bridging Virtual Technology and Real-World Applications

The newly acquired funds will not only support the expansion of Turbine’s oncology offerings but also allow the company to enhance its virtual lab capabilities. The sophisticated ‘lab-in-the-loop’ mechanism will enable Turbine to generate proprietary perturbation datasets, fine-tuning its foundational virtual cell model for various assays and tissue types. Turbine's no-code Virtual Lab platform integrates seamlessly with existing pharmaceutical workflows and systems, making it easier for researchers to incorporate virtual assays into their research paradigms.

Ascan Voswinckel, Head of Beiersdorf Venture Capital, highlighted the potential of AI technologies in drug research.

“Investing in Turbine aligns with our commitment to advancing deep-tech initiatives that could shape the landscape of skin research in the future. The prospects of AI-driven virtual cell models are immense, especially in understanding the interactions of skincare ingredients with various skin conditions.”

The Future of Drug Discovery

With its innovative approach, Turbine is on a mission to redefine the drug discovery process. Its foundational virtual cell model leverages AI to simulate biological experiments, thus allowing researchers to rapidly explore millions of biological ideas beyond what is possible in physical labs. This transformation makes significant strides toward achieving acceleration in drug development, particularly within the constrained timelines many contemporary researchers face.

Established collaborations with prominent biopharmaceutical firms such as MSD (known as Merck in the US), AstraZeneca, and Bayer validate Turbine's ability to rationalize experiments across numerous discovery programs.

With a focus on shaping the future of biopharmaceutical research and development, Turbine stands as a beacon of innovation, marrying biology with engineering disciplines. This unique fusion aims to empower researchers with actionable insights and enhance the potential for therapeutic advancements promptly.

For further updates, interested parties can visit Turbine's website or connect through their LinkedIn page.